Clinical Trials Logo

Palbociclib clinical trials

View clinical trials related to Palbociclib.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT04526028 Recruiting - Breast Cancer Clinical Trials

Palbociclib in Combination With Fulvestrant Versus Fulvestrant in Advanced Breast Cancer: A Real-world Study in China

Start date: September 13, 2019
Phase:
Study type: Observational

The purpose of this study is to evaluate efficacy and safety of CDK4/6 inhibitor Palbociclib in combination with Fulvestrant versus Fulvestrant in female patients with HR+/HER2- advanced breast cancer in a real world setting in China. Primary study endpoint: progression-free survival (PFS). Secondary study endpoints: overall survival (OS), overall response rate (ORR), clinical benefit rate (CBR), objective response duration (DOR) and safety.